Brain Imaging Track

The 2023 meeting features a dedicated track on Brain Imaging. The program has been structured to improve your knowledge in neuroimaging, from basic concepts to more advanced applications, addressing several important subjects. Sessions include:

Thursday, January 26

1:30–3:30 pm PT

Neuroimaging Applications in the General Nuclear Medicine Clinic
Co-Sponsored by the SNMMI Brain Imaging Council and General Clinical Nuclear Medicine Council
Organizers: Lionel S. Zuckier, MD, MBA, FRCPC; Saeed Elojeimy, MD, PhD
Moderators: Lionel S. Zuckier, MD, MBA, FRCPC

Session Description
The session will focus on traditional “neuro” imaging applications, excluding functional brain imaging, performed in the general nuclear medicine clinic. Emphasis during this session will be placed on the clinical performance and interpretation of these examinations. The target audience includes physicians and technologists, including trainees. The neurologic, non-functional brain imaging examinations serve a vital role in the nuclear medicine armamentarium. As rarely performed examinations, many practitioners of nuclear medicine may have rarely if ever performed some of these examinations and may not have reviewed this material since their training and board examinations. This session will serve as a succinct survey and review of the main material. We anticipate that attendees will come away with new knowledge regarding the existence, performance, and interpretation of these examinations such that they will be oriented to the point of being able to participate in these examinations at their institutions when needed, with the assistance of written guidelines and assistance from colleagues.

Session Objectives

  • Summarize the status of brain perfusion imaging in the evaluation of brain death
  • List three pearls and pitfalls for performing and interpreting CSF imaging
  • Describe three uncommon head and neck imaging applications

Presentations
Death by Neurologic Criteria – Is Anything New in Brain Death Other than the Name?
Lionel S. Zuckier, MD, MBA, FRCPC, Montefiore Medical Center

Refresher on CSF Imaging Procedures and Interpretation
Saeed Elojeimy, MD, PhD, Medical University of South Carolina

Head and Neck Studies in the General Nuclear Medicine Clinic
David H. Lewis, MD, University of Washington


3:45–5:45 pm PT

Clinical Molecular Brain Imaging – Case-Based Approach 
Sponsored by the SNMMI Brain Imaging Council
Organizers: Javier Arbizu, MD, PhD; Satoshi Minoshima, MD, PhD, FSNMMI
Moderators: Satoshi Minoshima, MD, PhD, FSNMMI; David H. Lewis, MD

Session Description
The overall goal of this session is to enhance clinicians’ ability to recognize and interpret molecular brain images obtained for neurological disorders including dementia, movement disorders, brain tumors, and other interesting cases.

Session Objectives

  • Recognize the common neuroimaging features related to the clinical symptoms and indications of dementing disorders, brain tumors, movement disorders, and to distinguish from other interesting neurological cases
  • Have a greater understanding of the molecular imaging modalities used for the clinical diagnosis of neurological conditions
  • Recognize the limitations of neuroimaging methods for diagnosis of such conditions

Presentations

Dementia
David H. Lewis, MD, University of Washington

Movement Disorders
Ming-Kai Chen, MD, PhD, Yale New Haven Hospital 

Brain Tumors
YingBing Wang, MD, University of California, San Francisco

Interesting Cases
Pedram Heidari, MD, Massachusetts General Hospital

 

6:30–8:30 pm PT

Neuro-Oncology: Imaging and Therapy 
Sponsored by the SNMMI Brain Imaging Council
Sponsored by the SNMMMI Brain Imaging Council
Organizers/Moderators: Phillip Kuo, MD, PhD; Neil B. Horner, MD

Session Description
Tumors of the central nervous system present many unique challenges for both imaging and therapy. Nuclear medicine physicians need to have a grasp of the basic physiology of the CNS and pathology of these tumors to understand the special requirements necessary for neuro-oncologic radiopharmaceuticals. Through the comprehension gained in this session, nuclear medicine physicians will better provide present and future care to patients with CNS tumors.

Session Objectives

  • Review the advantages of amino acid PET imaging for tumors of the central nervous system
  • Understand the clinical role of various imaging techniques in the diagnosis and treatment of brain tumors
  • Discuss the unique challenges and strategies for theranostics of tumors of the central nervous system

Presentations

Amino Acid PET for CNS Tumors
Jonathan McConathy, MD, PhD, University of Alabama, Birmingham

Multimodal Assessment of CNS Tumors
Neil B. Horner, MD

Theranostics – Unique Approaches to a Special Problem
Delphine L. Chen, MD, University of Washington/Seattle Cancer Care Alliance

Q&A

Friday, January 27

8:00–10:00 am PT


Molecular Imaging of Neuropsychiatric Disorders

Sponsored by the SNMMI Brain Imaging Council
Organizers: James Brasic, MD; Ansel T. Hillmer, PhD
Moderators: Noble George, Ansel T. Hillmer, PhD

Session Description
Neuropsychiatric disorders afflict a sizable proportion of the population around the world. The absence of reliable and valid tools to identify specific nervous and mental conditions is a major obstacle to the utilization of precision medicine to tailor treatment plans to the needs of individual patients. Breakthroughs in the applications of basic science to optimize molecular imaging techniques promise to give providers biomarkers for the signatures pathognomonic for the diagnosis of neuropsychiatric disorders. The purpose of this course is to educate the audience in recent advances in translational research of brain imaging in neuropsychiatric conditions. The intended audience is providers and scientists who work with people with neuropsychiatric conditions. Audience members will learn innovative advances in molecular imaging research of neuropsychiatric conditions.

Session Objectives

  • Utilize PET imaging to visualize immune function in neuropsychiatric disorders
  • Utilize molecular imaging advances to visualize alcohol use disorder
  • Apply modeling to visualize brain immune function
  • Utilize molecular imaging for autism spectrum disorder

Presentations

Visualizing Inflammation in Neurological Disease using PET Imaging
Aisling Chaney, PhD, Mallinckrodt Institute of Radiology

Imaging Neuroinflammation in individuals with Alcohol Use Disorder
Corinde E. Wiers, PhD, University of Pennsylvania

PET Imaging of Brain Immune Function: Modeling Considerations and Clinical
Ansel Hillmer, PhD, Yale School of Medicine

Molecular Imaging of Autism Spectrum Disorder
James Brasic, MD, MPH, Johns Hopkins School of Medicine

 

10:15 am–12:15 pm PT

Brain Injury and Traumatic Encephalopathy Syndrome 
Sponsored by the SNMMI Brain Imaging Council
Organizer: Donna J. Cross, PhD 
Moderator: Neil B. Horner, MD

Session Description
The overall goal of this session is to enhance physicians understanding of traumatic brain injury (TBI) and traumatic encephalopathy syndromes (TES) including imaging methods to better diagnose, treat and understand such conditions. Talks will present background in the clinical work-up and management of TBI and TES as well as MRI and molecular imaging modalities under development for research applications

Session Objectives

  • Examine the clinical symptoms and indications of acute and chronic TBI
  • Correlate the clinical and imaging findings for diagnosis of traumatic brain injury and traumatic encephalopathy syndrome
  • Recognize the areas of need for developing and improving the brain imaging methods for research and diagnosis

Presentations

Clinical Features of Brain Injury and Traumatic Encephalopathy Syndrome 
Cathra Halabi, MD, University of California, San Francisco

The TRACK-TBI (Transforming Research and Clinical Knowledge in TBI) Study
Pratik Mukherjee, MD, PhD, University of California, San Francisco

Molecular Imaging for Research of TBI and TES
Donna J. Cross, PhD, University of Utah

 

1:15–3:15 pm PT

Molecular Brain Imaging in Dementia:  Current Status and Future Directions 
Sponsored by the SNMMI Brain Imaging Council
Organizers: Satoshi Minoshima, MD, PhD, FSNMMI; Donna J. Cross, PhD
Moderators: Peter Herscovitch, MD, FACP, FRCPC, FSNMMI; Satoshi Minoshima, MD, PhD, FSNMMI

Session Description
The overall goal of this session is to enhance participants’ knowledge of the status of molecular brain imaging of dementia including new appropriate use criteria, understanding of newly recognized diseases and their imaging features, and controversies and future directions of molecular brain imaging. Such knowledge will help communication with referral physicians, understand research opportunities, and advance clinical practice.

Session Objectives

  • Examine the appropriate use criteria for the application of Amyloid and Tau PET imaging in the clinical management of dementia patients
  • Recognize the new and evolving categories and sub-types of dementing disorders 
  • Discuss the controversies and future directions in dementia imaging modalities

Presentations

New Appropriate Use of Amyloid PET and Tau PET
Peter Herscovitch, MD, FACP, FRCPC, FSNMMI, National Institutes of Health

New Diseases and Evolving Disease Categories of Neurodegenerative Dementias
Satoshi Minoshima, MD, PhD, FSNMMI, University of Utah

From FDG PET to Amyloid / Tau PET: Unanswered Questions and Future Perspectives
William Jagust, MD, UC Berkeley

Panel Discussion – Controversies: Anti-Amyloid Therapies, Cost of Care, and Future Directions
All speakers and moderator

 

3:45–5:45 pm PT

Quantification Methods and AI-driven Imaging of Neurodegeneration 
Sponsored by the SNMMI Brain Imaging Council
Organizer: Ansel T. Hillmer, PhD
Moderator: Ansel T. Hillmer, PhD; Ciprian Catana, MD, PhD

Session Description
This session will review recent developments in PET quantification relevant to brain imaging and discuss the benefits of dynamic imaging in this context. It will also summarize AI methods that have been proposed for enhancing the PET data as well as potential uses of AI techniques for neurodegenerative disease diagnosis and prediction.

Session Objectives

  • Describe the role of PET quantification in neurodegenerative disease
  • Explain deep learning enabled approaches to enhance the PET image quality 
  • Identify potential clinical applications of artificial intelligence in neurodegeneration

Presentations

PET Quantification with a Focus on AD
Suzanne L. Baker, University of California Berkeley 

Dynamic vs. Static Imaging: When, Why, and How
Ansel T. Hillmer, PhD, Yale School of Medicine

AI in Neurodegeneration - Image Enhancement
Ciprian Catana, MD, PhD, Massachusetts General Hospital and Harvard Medical School

AI in Neurodegeneration - Diagnosis and Prediction
Greg Zaharchuk, PhD, Stanford University School of Medicine

Saturday, January 28

8:00–10:00 am PT

Amyloid and Tau PET: Clinical and Research Updates
Sponsored by the SNMMI Brain Imaging Council
Organizers: Javier Arbizu, MD, PhD; Gil Rabinovici, MD; Shadi Abdar Esfahani, MD, MPH
Moderators: Gil Rabinovici, MD; Shadi Abdar Esfahani, MD, MPH

Session Description
The overall goal of this session is to review and discuss the status and regulatory challenges in molecular imaging of the brain and issues related to reimbursement for novel radiotracers and onboarding next generation of imaging probes.

Session Objectives

  • Identify the regulatory challenges in brain molecular imaging 
  • Discuss on the IDEAS and current reimbursement for neuroradiotracers 
  • Discuss on tau radiotracers and next generation of molecularly targeted probes


Presentations

Regulatory Challenges in Brain Molecular Imaging
Peter Herscovitch, MD, FACP, FRCPC, FSNMMI

IDEAS Session and Current Reimbursement for Neurotracers
Gil Rabinovici, MD, University of California, San Francisco

Tau Tracer Updates:  Next Generation
Renaud La Joie, PhD

 

10:30 AM–12:30 pm PT

Parkinsonian Syndromes
Sponsored by the SNMMI Brain Imaging Council
Organizers: Marc Daniel Benayoun, PhD; Phillip Kuo, MD, PhD
Moderators: John P. Seibyl, MD; Phillip Kuo, MD, PhD

Session Description
In this session focusing on Parkinson’s disease and other Parkinsonian syndromes, clinicians will learn to optimize their current clinical practice of dopamine transporter imaging, understand current and future clinical implications from the largest longitudinal study of Parkinson’s disease, and realize the potential of future radiopharmaceuticals for Parkinsonian syndromes.

Session Objectives

  • Optimize the performance and interpretation of dopamine transporter SPECT for Parkinsonian syndromes.
  • Understand the valuable imaging insights for both clinic and trials from the largest longitudinal study of Parkinson’s disease.
  • Discuss the challenges and opportunities of the many new and promising radiopharmaceuticals under development for Parkinsonian syndromes

Presentations

Clinical Dopamine Imaging
Phillip Kuo, MD, PhD

Still Learning After All These Years:  Fresh Insights About PD from the Parkinsons Progression Marker Initiative (PPMI)
John P. Seibyl, MD

New and Promising Tracers for Parkinsonian Syndromes
Ephraim E. Parent, MD, PhD

Q&A

 

1:30–3:30 pm PT

Molecular Imaging of Acute or Rapidly Progressing Dementing Disorders
Sponsored by the SNMMI Brain Imaging Council
Organizers: Javier Arbizu, MD, PhD; Gil Rabinovici, MD; Shadi Abdar Esfahani, MD, MPH
Moderators: Gil Rabinovici, MD; Shadi Abdar Esfahani, MD, MPH

Session Description
The overall goal of this session is to address the unmet clinical needs for accurate and rapid diagnosis, and imaging guidance of treatment of acute and rapid onset dementia disorders, focused on frontotemporal dementia, CJD, prionic and autoimmune encephalitis as well as neuroinflammation.

Session Objectives

  • Identify the pattern of specific and most common acute and rapid onset dementia disorders
  • Correlate the clinical and imaging findings for accurate diagnosis of rapid onset dementing disorders
  • Recognize the areas of need for developing and improving the brain imaging methods.

Presentations

Frontotemporal Dementia (FTD)
Maura Malpetti, MD

CJD, Prionic and Autoimmune Encephalitis 
Gregory S. Day, MD

Dementia with Lewy Bodies 
Kirk Frey, MD, PhD

 

4:00–6:00 pm PT

Imaging of Epilepsy and Challenging Patients
Sponsored by the SNMMI Brian Imaging Council
Organizers: Ming-Kai Chen, MD, PhD; James R. Brasic, MD
Moderators: Ming-Kai Chen, MD, PhD; James R. Brasic, MD

Session Description
Epilepsy and seizures affect almost three million Americans of all ages. Tremendous advances have been made in epilepsy treatment over the years. Despite these advances, a sizable proportion of patients continue to have seizures and eventually require surgical intervention. This session will provide participants with the tools to stay up to date on new advances in the treatment of epilepsy and current molecular imaging tools as well as promising new molecular imaging tools for pre-surgical localization for epilepsy. In addition, we will provide useful tools including behavioral training to complete the imaging acquisition of challenging patients without conscious sedation.

Session Objectives

  • Describe the surgical treatment options for patients with epilepsy, including neurostimulation, laser ablation, and resection
  • Examine the SPECT and PET molecular imaging for accurate presurgical localization of seizure focus
  • List the useful tools including behavioral training to complete the imaging acquisition of challenging patients


Presentations

Epilepsy Surgery Treatment Options and the Role of Presurgical Localization Tests
Robert Knowlton, MD, UCSF Weill Institute for Neurosciences

SPECT/PET Imaging in Workup of Epilepsy
Gagandeep Choudhary, MD, Oregon Health and Science University

Modern PET Imaging for Epilepsy:  Beyond FDG
Ming-Kai Chen, MD, PhD, Yale University/Yale New Haven Hospital

Scanning Challenging Patients
James R. Brasic, MD, Johns Hopkins University School of Medicine